CurrentViva Health PlanPolicy s-033

Levocarnitine Injection

Customize your policy alerts

Sign up for vivahealthplan Policy s-033 alerts

Get alerted when Policy s-033 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

This policy establishes medical necessity criteria for levocarnitine injection for VIVA Medicare and VIVA Commercial members. Coverage requires an FDA-approved indication, compliance with applicable Medicare requirements, and medical-record documentation supporting medical necessity.

Policy Summary

PayerViva Health Plan

PolicyLevocarnitine Injection

Policy CodePolicy s-033

Change TypeNo material change

Effective DateN/A

Last ReviewSep 15, 2026

Next Review DateN/A

Key ActionThe patient's medical record must clearly document the specific clinical circumstances supporting the medical necessity of levocarnitine injection.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

2FDA-approved indication categories

Inborn errors of metabolismSecondary carnitine deficiency

ESRD with dialysisDialysis-related deficiency

FDA indication requiredCoverage restriction

FDA-Approved Indications

Policy Summary

PayerViva Health Plan

PolicyLevocarnitine Injection

Policy CodePolicy s-033

Change TypeNo material change

Effective DateN/A

Last ReviewSep 15, 2026

Next Review DateN/A

Key ActionThe patient's medical record must clearly document the specific clinical circumstances supporting the medical necessity of levocarnitine injection.

SourceLink

On This Page

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentViva Health PlanPolicy s-033

Levocarnitine Injection

Customize your policy alerts

Sign up for vivahealthplan Policy s-033 alerts

Get alerted when Policy s-033 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerViva Health Plan

PolicyLevocarnitine Injection

Policy CodePolicy s-033

Change TypeNo material change

Effective DateN/A

Last ReviewSep 15, 2026

Next Review DateN/A

Key ActionThe patient's medical record must clearly document the specific clinical circumstances supporting the medical necessity of levocarnitine injection.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

2FDA-approved indication categories

Inborn errors of metabolismSecondary carnitine deficiency

ESRD with dialysisDialysis-related deficiency

FDA indication requiredCoverage restriction

FDA-Approved Indications

Policy Summary

PayerViva Health Plan

PolicyLevocarnitine Injection

Policy CodePolicy s-033

Change TypeNo material change

Effective DateN/A

Last ReviewSep 15, 2026

Next Review DateN/A

Key ActionThe patient's medical record must clearly document the specific clinical circumstances supporting the medical necessity of levocarnitine injection.

SourceLink

On This Page

FDA-Approved Indications

Covered when all of the following are met:

Coverage requirements

FDA-approved indication
- Inborn error of metabolism: Acute or chronic treatment of a patient with an inborn error of metabolism that results in secondary carnitine deficiency.
- End-stage renal disease with dialysis: Prevention or treatment of carnitine deficiency in a patient with end-stage renal disease who is undergoing dialysis.

Documentation and Coverage Requirements

Documentation Required

Clinical Documentation Required

The patient's medical record must clearly document the specific clinical circumstances supporting the medical necessity for levocarnitine injection.

Document the clinical circumstances that establish medical necessity for the requested services.

Denial Risk

Denial Risk: Nonapproved Use or Insufficient Documentation

Coverage is limited to levocarnitine injection used for an FDA-approved indication and must meet all other applicable Medicare statutory and regulatory requirements. Services may be denied when the indication is non-FDA-approved or when the medical record does not adequately support medical necessity.

Non-FDA-approved indication
Inadequate or missing documentation of the specific clinical circumstances supporting medical necessity
Failure to meet applicable Medicare statutory or regulatory requirements

Clinical Background

Levocarnitine injection is used to address carnitine deficiency in defined clinical settings. Covered use includes the acute or chronic treatment of patients with an inborn error of metabolism resulting in secondary carnitine deficiency, and the prevention or treatment of carnitine deficiency in patients with end-stage renal disease who are undergoing dialysis.